Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics (NASDAQ: KYTX) is your centralized source for updates on innovative CAR T-cell therapies targeting autoimmune diseases. This page aggregates official press releases, clinical trial progress, and strategic developments from the clinical-stage biopharmaceutical leader.
Investors and researchers will find timely updates on KYV-101 trials, regulatory milestones, and scientific partnerships. Our curated news collection covers B cell-targeting therapies, rheumatology/neurology research advancements, and manufacturing innovations without speculative commentary.
Key content includes updates on lupus nephritis studies, multiple sclerosis treatment developments, and analysis of Kyverna's dual-platform strategy (autologous/allogeneic). Bookmark this page for streamlined access to critical updates about CD19-targeting therapies and their potential to reset immune responses in autoimmune conditions.
Kyverna Therapeutics (NASDAQ: KYTX) has provided its Q4 and full-year 2024 financial results, reporting significant progress in its autoimmune CAR T-cell therapy programs. The company ended 2024 with $286.0 million in cash, projecting runway into 2027.
Key developments include:
- 70% enrollment completion in the registrational Phase 2 KYSA-8 trial for stiff person syndrome, with topline data expected in 1H 2026
- Completed initial patient cohort enrollment for myasthenia gravis Phase 2 trial, with interim data expected in 2H 2025
- Advancing two Phase 1/2 trials in lupus nephritis with data expected in 2H 2025
The company reported a net loss of $127.5 million ($3.33 per share) for 2024, compared to $60.4 million ($89.61 per share) in 2023. Net cash used in operations was $114.3 million, up from $52.4 million in 2023.
Kyverna Therapeutics (Nasdaq: KYTX), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has announced its upcoming participation in the Leerink Partners Global Biopharma Conference.
The company's CEO, Warner Biddle, is scheduled to present at the conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Investors section of Kyverna's website at ir.kyvernatx.com. The presentation recording will remain available for replay on the website for 30 days after the conference.
Kyverna Therapeutics (NASDAQ: KYTX) has appointed Naji Gehchan, M.D., MBA, as Chief Medical and Development Officer. Dr. Gehchan brings 20 years of U.S. and international experience, particularly in immunology, joining from Eli Lilly where he most recently led clinical development for imlunestrant.
In his new role, Dr. Gehchan will lead Kyverna's research, clinical development, and medical affairs functions as the company advances KYV-101 to late-stage development. He previously held senior leadership positions at Eli Lilly, including Associate VP of Sales for U.S. Diabetes and CMO for Lilly France, Belgium, and Netherlands.
As part of this transition, Dominic Borie, M.D., Ph.D., the founding CEO and recent President of R&D, will move to a Strategic Advisor role. The company will grant Dr. Gehchan an option to purchase 425,000 shares, vesting over four years with 25% vesting after one year and 1/48th monthly thereafter.
Kyverna Therapeutics (NASDAQ: KYTX) announced its 2025 strategic priorities, focusing on developing CAR T cell therapies for autoimmune diseases. The company reported 40% enrollment completion in their pivotal Phase 2 trial of KYV-101 for stiff person syndrome, targeting BLA filing in 2026. They're also advancing trials in myasthenia gravis and lupus nephritis.
Key upcoming milestones include completing pivotal Phase 2 enrollment for stiff person syndrome by mid-2025, reporting Phase 2 data in first half 2026, and filing for BLA in 2026. For myasthenia gravis, they plan to confirm the registrational path in first half 2025 and report interim Phase 2 data in second half 2025. The company is also developing KYV-102, featuring whole blood rapid manufacturing to improve patient access.
Kyverna maintains a strong financial position with $321.6 million in cash and equivalents as of September 30, 2024, providing runway into 2027.
Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Warner Biddle, will deliver a presentation outlining Kyverna's 2025 strategic priorities and key milestones on Monday, January 13, 2025, at 5:15 p.m. PST.
Interested parties can access a live audio webcast of the presentation through the Investors section of Kyverna's website at https://ir.kyvernatx.com/. The presentation recording will remain available on the website for 30 days after the conference.
Kyverna Therapeutics announced three key leadership appointments to support its next growth phase in developing cell therapies for autoimmune diseases. Dan Maziasz joins as Chief Business Officer, bringing 25 years of experience from companies like Atara Biotherapeutics and Kite Pharma. Cara Bauer becomes Chief Human Resources Officer, with over 25 years of global HR leadership experience, notably at Kite and Netflix. Tracy Rossin joins as SVP of Corporate Affairs, Communications and Investor Relations, bringing 20 years of strategic communications experience from Kite and AstraZeneca.
As part of his appointment, Maziasz received an inducement grant of options to purchase 350,000 shares at $4.86 per share, vesting over four years with 25% vesting after one year and the remainder monthly.
Kyverna Therapeutics presented updated clinical data for KYV-101, their CD19 CAR T-cell therapy for lupus nephritis (LN) treatment. The data shows sustained efficacy and durability in patients treated with the target dose of 1×108 CD19 CAR T cells, with four out of six patients having at least six months of follow-up. Key findings demonstrate deep B cell depletion, immune system reset, stabilized eGFR, preserved kidney function, and improved SLE activity. The treatment allowed elimination of immunosuppressants and reduction of glucocorticoids while maintaining a manageable safety profile with no high-grade CRS or ICANS observed.
Kyverna Therapeutics reported Q3 2024 financial results and business updates. The company appointed Warner Biddle as CEO and made multiple key leadership appointments. They presented clinical data for KYV-101 in various autoimmune conditions at ECTRIMS and plan to share updated lupus nephritis data at ACR Convergence 2024.
The company reported a net loss of $34.3 million ($0.80 per share) for Q3 2024, compared to $15.5 million in Q3 2023. Cash position remains strong at $321.6 million as of September 30, 2024. Net cash used in operations was $77.2 million for the first nine months of 2024.
Kyverna Therapeutics, Inc. (KYTX) has appointed Mert Aktar as an independent director to its Board of Directors. Mr. Aktar brings over two decades of biopharmaceutical experience, combining technical leadership in cell and gene therapy with a proven track record in corporate development. He currently serves as CEO of Receptive Bio and holds board positions with UCLA Technology Development Group and ReAlta Life Sciences.
Previously, Mr. Aktar was Senior Vice President and Global Head of Corporate Development & Strategy at Kite Pharma, where he played a key role in establishing Kite's global leadership in cell therapy. He also held senior leadership positions at various biotech and large pharma organizations, including Shire, where he facilitated multi-billion-dollar transactions and led large-scale manufacturing operations.
Kyverna's CEO, Warner Biddle, expressed confidence that Mr. Aktar's strategic experience and technical expertise in cell therapy will be invaluable as the company advances KYV-101 into later stages of development and builds on its CAR T leadership in autoimmune diseases.
Kyverna Therapeutics presented patient data at ECTRIMS 2024, showcasing the potential of KYV-101 for treating neuroinflammatory diseases. The company shared case reports from 11 patients with stiff-person syndrome, myasthenia gravis, and multiple sclerosis, demonstrating initial efficacy and safety of KYV-101. Key biomarkers indicate its potential to durably modify neuroinflammatory diseases through immune system reset.
Highlights include:
- Improved mobility and reduced autoantibody titers in stiff-person syndrome patients
- Sustained disease control in myasthenia gravis patients
- Significant reduction in oligoclonal bands in multiple sclerosis patients
- No severe CRS or ICANS observed across 41 treated patients
Kyverna also presented posters on the design and methods of its clinical trials for KYV-101 in neuroinflammatory diseases.
